POAG surgical outcomes affected by DM

Article

According to recently published data, POAG patients with diabetes mellitus (DM) undergoing primary trabeculectomy with MMC do not achieve the same long-term IOP control compared to patients without DM.

According to recently published data, POAG patients with diabetes mellitus (DM) undergoing primary trabeculectomy with MMC do not achieve the same long-term IOP control compared to patients without DM.

Dr Simon K. Law, Glaucoma Division, Jules Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, California, USA, studied 41 eyes of 29 patients with DM and 81 eyes of 64 patients without DM. Patients with DM without retinopathy were retrospectively compared with a control group without DM. Surgical success was defined as IOP ≤15 and >5 mmHg without complications or further glaucoma surgery.

At 60 months the Kaplan–Meier cumulative survival rates were 57.8±9.3% for the DM group and 68.6±5.3% for the control group. Mean postoperative IOP of the control group was statistically significantly lower than the DM group at the two, three, six and seven-year follow-up visits. The rates of postoperative complications and additional glaucoma surgeries were the same between the two groups.

POAG patients with DM without retinopathy undergoing primary trabeculectomy with MMC could have a lower long-term surgical survival rate, compared to patients without DM.

The abstract can be read in the latest issue of the British Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.